04/12/2024
5:06 AM | Larimar Therapeutics, Inc. (Filer)
Larimar Therapeutics (Filer)
| Form PRE 14A | |
03/15/2024
3:37 PM | Flynn James E (Filed by)
Larimar Therapeutics, Inc. (Subject)
Larimar Therapeutics (Subject)
| Form SC 13D/A | |
03/14/2024
4:07 PM | Larimar Therapeutics, Inc. (Filer)
Larimar Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/14/2024
4:07 PM | Larimar Therapeutics, Inc. (Filer)
Larimar Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/16/2024
1:37 PM | Deerfield Healthcare Innovations Fund, L.P. (Reporting)
DEERFIELD MANAGEMENT COMPANY, L.P. (0001009258) (Reporting)
Deerfield Mgmt HIF, L.P. (Reporting)
Deerfield Mgmt III, L.P. (Reporting)
Deerfield Mgmt IV, L.P. (Reporting)
Deerfield Mgmt L.P. (Reporting)
DEERFIELD PARTNERS, L.P. (Reporting)
Deerfield Private Design Fund III, L.P. (Reporting)
Deerfield Private Design Fund IV, L.P. (Reporting)
Flynn James E (Reporting)
Larimar Therapeutics, Inc. (Issuer)
Larimar Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
1:11 PM | Flynn James E (Filed by)
Larimar Therapeutics, Inc. (Subject)
Larimar Therapeutics (Subject)
| Form SC 13D/A | |
02/15/2024
4:20 PM | Flynn James E (Filed by)
Larimar Therapeutics, Inc. (Subject)
Larimar Therapeutics (Subject)
| Form SC 13D/A | |
|
02/15/2024
3:21 PM | Larimar Therapeutics, Inc. (Issuer)
Larimar Therapeutics (Issuer)
THOMAS FRANK E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2024
7:57 PM | Blue Owl Capital Holdings LP (Filed by)
Larimar Therapeutics, Inc. (Subject)
Larimar Therapeutics (Subject)
| Form SC 13G | |
02/14/2024
3:46 PM | Larimar Therapeutics, Inc. (Subject)
Larimar Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
| Form SC 13G/A | |
02/14/2024
7:55 AM | Larimar Therapeutics, Inc. (Subject)
Larimar Therapeutics (Subject)
Verition Fund Management LLC (Filed by)
| Form SC 13G | |
02/14/2024
5:06 AM | Larimar Therapeutics, Inc. (Filer)
Larimar Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/12/2024
6:03 AM | Larimar Therapeutics, Inc. (Filer)
Larimar Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/19/2024
3:31 PM | BEN-MAIMON CAROLE (Reporting)
Larimar Therapeutics, Inc. (Issuer)
Larimar Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/19/2024
3:31 PM | Clayton Russell (Reporting)
Larimar Therapeutics, Inc. (Issuer)
Larimar Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/19/2024
3:32 PM | Celano Michael (Reporting)
Larimar Therapeutics, Inc. (Issuer)
Larimar Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/19/2024
3:33 PM | Larimar Therapeutics, Inc. (Issuer)
Larimar Therapeutics (Issuer)
Shankar Gopi (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/05/2023
3:32 PM | Larimar Therapeutics, Inc. (Issuer)
Larimar Therapeutics (Issuer)
SHERMAN JEFFREY W (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
10/05/2023
3:33 PM | Larimar Therapeutics, Inc. (Issuer)
Larimar Therapeutics (Issuer)
SHERMAN JEFFREY W (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/18/2023
1:45 PM | JANUS HENDERSON GROUP PLC (Filed by)
Larimar Therapeutics, Inc. (Subject)
Larimar Therapeutics (Subject)
| Form SC 13G | |
08/14/2023
7:00 AM | Larimar Therapeutics, Inc. (Filer)
Larimar Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/10/2023
6:03 AM | Larimar Therapeutics, Inc. (Filer)
Larimar Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/25/2023
6:02 AM | Larimar Therapeutics, Inc. (Filer)
Larimar Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/24/2023
4:46 PM | Barrett Peter (Reporting)
Larimar Therapeutics, Inc. (Subject)
Larimar Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/18/2023
3:13 PM | Clayton Russell (Reporting)
Larimar Therapeutics, Inc. (Issuer)
Larimar Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
07/18/2023
3:15 PM | Clayton Russell (Reporting)
Larimar Therapeutics, Inc. (Issuer)
Larimar Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/17/2023
3:08 PM | Larimar Therapeutics, Inc. (Filer)
Larimar Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/15/2023
3:03 PM | Larimar Therapeutics, Inc. (Filer)
Larimar Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/15/2023
6:05 AM | Larimar Therapeutics, Inc. (Filer)
Larimar Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/11/2023
5:31 PM | DEERFIELD MANAGEMENT COMPANY, L.P. (0001009258) (Reporting)
Flynn James E (Reporting)
Larimar Therapeutics, Inc. (Issuer)
Larimar Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
